Determinants of utilisation differences for cancer medicines in Belgium, Scotland and Sweden.

ABSTRACT:

Background

Little comparative evidence is available on utilisation of cancer medicines in different countries and its determinants. The aim of this study was to develop a statistical model to test the correlation between utilisation and possible determinants in selected European countries.

Methods

A sample of 31 medicines for cancer treatment that obtained EU-wide marketing authorisation between 2000 and 2012 was selected. Annual data on medicines' utilisation covering the in- and out-patient public sectors were obtained from national authorities between 2008 and 2013. Possible determinants of utilisation were extracted from HTA reports and complemented by contacts with key informants. A longitudinal mixed effect model was fitted to test possible determinants of medicines ut

SUBMITTER: Ferrario A 

PROVIDER: S-EPMC5641289 | biostudies-literature | 2017 Dec

REPOSITORIES: biostudies-literature